Literature DB >> 23600433

Causes and circumstances of death in pulmonary arterial hypertension.

Adriano R Tonelli1, Vineesha Arelli, Omar A Minai, Jennie Newman, Nancy Bair, Gustavo A Heresi, Raed A Dweik.   

Abstract

RATIONALE: The causes and circumstances surrounding death are understudied in patients with pulmonary arterial hypertension (PAH).
OBJECTIVES: We sought to determine the specific reasons and characteristics surrounding the death of patients with PAH.
METHODS: All deaths of patients with pulmonary hypertension (PH) followed in the Cleveland Clinic Pulmonary Vascular Program were prospectively reviewed by the PH team. A total of 84 patients with PAH (age 58 ± 14 yr; 73% females) who died between June 2008 and May 2012 were included.
MEASUREMENTS AND MAIN RESULTS: PH was determined to be the direct cause of death (right heart failure or sudden death) in 37 (44%) patients; PH contributed to but did not directly cause death in 37 (44%) patients; and the death was not related to PH in the remaining cases (n = 7; 8.3%). In three (3.6%) patients the final cause of death could not be adequately assessed. Most patients died in a healthcare environment and most received PH-specific therapies. In our cohort, 50% of all patients with PAH and 75.7% of those who died of right heart failure received parenteral prostanoid therapy. Less than half of patients had advanced healthcare directives.
CONCLUSIONS: Most patients with PAH in our cohort died of their disease; however, right ventricular failure or sudden death was the sole cause of death in less than half of patients.

Entities:  

Mesh:

Year:  2013        PMID: 23600433      PMCID: PMC3778730          DOI: 10.1164/rccm.201209-1640OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

Review 1.  Diagnosis and assessment of pulmonary arterial hypertension.

Authors:  David B Badesch; Hunter C Champion; Miguel Angel Gomez Sanchez; Marius M Hoeper; James E Loyd; Alessandra Manes; Michael McGoon; Robert Naeije; Horst Olschewski; Ronald J Oudiz; Adam Torbicki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

Authors:  L J Rubin; J Mendoza; M Hood; M McGoon; R Barst; W B Williams; J H Diehl; J Crow; W Long
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

3.  Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history.

Authors:  A Miller; J C Thornton; R Warshaw; H Anderson; A S Teirstein; I J Selikoff
Journal:  Am Rev Respir Dis       Date:  1983-03

4.  Pulmonary hypertension surveillance--United States, 1980-2002.

Authors:  Alexandra Hyduk; Janet B Croft; Carma Ayala; Kan Zheng; Zhi-Jie Zheng; George A Mensah
Journal:  MMWR Surveill Summ       Date:  2005-11-11

5.  Prediction of life expectancy in patients with primary pulmonary hypertension. A retrospective nationwide survey from 1980-1990.

Authors:  O Okada; N Tanabe; J Yasuda; Y Yoshida; K Katoh; T Yamamoto; T Kuriyama
Journal:  Intern Med       Date:  1999-01       Impact factor: 1.271

6.  Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.

Authors:  Marius M Hoeper; Nazzareno Galié; Srinivas Murali; Horst Olschewski; Melvyn Rubenfire; Ivan M Robbins; Harrison W Farber; Vallerie McLaughlin; Shelley Shapiro; Joanna Pepke-Zaba; Joerg Winkler; Ralf Ewert; Christian Opitz; Volker Westerkamp; Jean-Luc Vachiéry; Adam Torbicki; Juergen Behr; Robyn J Barst
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

7.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

8.  Reference equations for the six-minute walk in healthy adults.

Authors:  P L Enright; D L Sherrill
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

Review 9.  ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.

Authors:  Vallerie V McLaughlin; Stephen L Archer; David B Badesch; Robyn J Barst; Harrison W Farber; Jonathan R Lindner; Michael A Mathier; Michael D McGoon; Myung H Park; Robert S Rosenson; Lewis J Rubin; Victor F Tapson; John Varga; Robert A Harrington; Jeffrey L Anderson; Eric R Bates; Charles R Bridges; Mark J Eisenberg; Victor A Ferrari; Cindy L Grines; Mark A Hlatky; Alice K Jacobs; Sanjay Kaul; Robert C Lichtenberg; Jonathan R Lindner; David J Moliterno; Debabrata Mukherjee; Gerald M Pohost; Robert S Rosenson; Richard S Schofield; Samuel J Shubrooks; James H Stein; Cynthia M Tracy; Howard H Weitz; Deborah J Wesley
Journal:  Circulation       Date:  2009-03-30       Impact factor: 29.690

10.  Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.

Authors:  Hubert Chen; Stephen C Shiboski; Jeffrey A Golden; Michael K Gould; Steven R Hays; Charles W Hoopes; Teresa De Marco
Journal:  Am J Respir Crit Care Med       Date:  2009-06-11       Impact factor: 21.405

View more
  71 in total

1.  Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Adriano R Tonelli; Mostafa K Ahmed; Laith Alkukhun; Frank Cikach; Kulwant Aulak; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2015-10-15       Impact factor: 21.405

2.  Are transcutaneous oxygen and carbon dioxide determinations of value in pulmonary arterial hypertension?

Authors:  Adriano R Tonelli; Laith Alkukhun; Frank Cikach; Mostafa Ahmed; Raed A Dweik
Journal:  Microcirculation       Date:  2015-05       Impact factor: 2.628

Review 3.  The right ventricle under pressure: evaluating the adaptive and maladaptive changes in the right ventricle in pulmonary arterial hypertension using echocardiography (2013 Grover Conference series).

Authors:  Alexis Harrison; Nathan Hatton; John J Ryan
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

4.  Is pulmonary hypertension a metabolic disease?

Authors:  Jarrod Barnes; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

5.  Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?

Authors:  Andrew Van Tosh; Kenneth J Nichols
Journal:  J Nucl Cardiol       Date:  2018-06       Impact factor: 5.952

Review 6.  Epidemiology and treatment of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Eleni Giannoulatou; David S Celermajer; Marc Humbert
Journal:  Nat Rev Cardiol       Date:  2017-06-08       Impact factor: 32.419

7.  Pulmonary arterial hypertension treatment guidelines: new answers and even more questions.

Authors:  Anna R Hemnes
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

Review 8.  Update in pulmonary vascular diseases 2013.

Authors:  Paul M Hassoun; Paul T Schumacker
Journal:  Am J Respir Crit Care Med       Date:  2014-10-01       Impact factor: 21.405

9.  Changes in main pulmonary artery diameter during follow-up have prognostic implications in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Scott Johnson; Laith Alkukhun; Ruchi Yadav; Raed A Dweik
Journal:  Respirology       Date:  2017-05-17       Impact factor: 6.424

Review 10.  The role of imaging in pulmonary hypertension.

Authors:  Meenal Sharma; Andrew T Burns; Kelvin Yap; David L Prior
Journal:  Cardiovasc Diagn Ther       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.